Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Single-arm Clinical Study of the Efficacy and Safety of INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer

NCT06747832 is registered in ClinicalTrials.gov with Guangzhou Ruixin Biotechnological Co., LTD as lead sponsor.

NCT NCT06747832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06747832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Single-arm Clinical Study of the Efficacy and Safety of INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer
Lead sponsor
Guangzhou Ruixin Biotechnological Co., LTD
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
December 15, 2024
Completion date
December 14, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer